[ad_1]
BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) is a clinical-stage pharmaceutical company. Committed to developing innovative treatments for advanced cancers, solid tumors and other serious diseases, today announced that Lisata President and CEO David J. Mazzo, Ph.D., will participate in the following events in April:
The 14th LD Micro Invitational Tournament (April 8-9, 2024)
Format: In-person and on-demand
Location: Sofitel New York New York
Presentation date: Tuesday, April 9, 2024
Demo Time: 10:00 AM Eastern Time
Demonstration Track: Track 4 – Montmartre
Register for the webcast: https://ldinv14.sequireevents.com/
Management will conduct one-on-one meetings with registered investors for the conference. Please contact your Lisata representative or Dean Summers at LD Micro using the contact information below (Dean@ldmicro.com) Register for events and schedule meetings with companies.
Webinar hosted by FORCE Family Office and Lisata Therapeutics (April 10, 2024)
Format: Webinar – Virtual
Webinar Date: Wednesday, April 10, 2024
Webinar Time: 12:00 PM Eastern Time / 9:00 AM Pacific Time
Webinar details will be provided upon reply approval.To register for the event, please visit www.forcefamilyoffice.com/events/healthcare/lisata-therapeutics-coming-april-10-2024
Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (April 17-18, 2024)
Format: virtual
Presentation date: Wednesday, April 17, 2024
Demo time: 1:30 PM ET
Management will conduct one-on-one meetings with registered investors for the conference.Please contact a Lisata representative using the contact information below, or events@noblecapitalmarkets.com Register for events and schedule meetings with companies.For more event information, please visit https://bit.ly/3VwVxbz.
European Immuno-Oncology Summit (April 23-25, 2024)
Format: In-person and on-demand
Location: Hilton Hotel Canary Wharf, London, UK
Presentation date: Tuesday, April 23, 2024
Demo time: 4:30pm BST / 11:30am ET
Conference Agenda: Modulating the Tumor Microenvironment
To register for the event, please visit www.immuno-oncologyeurope.com.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on discovering, developing and commercializing innovative therapies for the treatment of advanced solid tumors and other critical diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that enables co-administration or combination of anti-cancer drugs to more effectively target and penetrate solid tumors.CendR platform based on Lisata® On the technology front, Lisata has established noteworthy commercial and R&D partnerships. The company expects to announce numerous clinical research and business milestones over the next two years and expects its current business and development plans to be funded through these milestones and available capital in early 2026. For more information about the company, please visit www.lisata.com.
touch:
Investors and media:
Lisata Therapeutics
John Menditto
Vice President of Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
[ad_2]
Source link